More than 50% of Johnson & Johnson’s MedTech portfolio is now in categories growing above 5%, compared with around 20% of its offering in 2018, the division’s executive VP and worldwide chairman Tim Schmid told investors earlier this month at the Wells Fargo Healthcare Conference.
“We’ve made north of $30 billion over the last couple years in high-growth spaces,